# TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

> **NCT03387917** · PHASE1 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TLD-1
- **DRUG:** Caelyx

## Key facts

- **NCT ID:** NCT03387917
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-12
- **Primary completion:** 2023-09-22
- **Final completion:** 2023-12-22
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The premature termination is based on the unexpectedly low patient accrual to the clinical trial and the strategic considerations in the development of the TLD-1 after having included 13 out of 14 patients in the comparative PK part.
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03387917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03387917, "TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03387917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*